Meet the Swedish Biotech that is Tackling NASH Through Mitochondria

Since there is no sun in Berlin anyways, we thought we might as well travel up north to Sweden to visit NeuroVive Pharmaceuticals. The company is located in the university town of Lund and is focussing on the development of compounds that target mitochondria, the cell’s powerhouses.

Neurovive_Map

Mission: NeuroVive is tackling a broad variety of diseases involving both traditional hereditary mitochondrial disorders such as mitochondrial myopathies and complex I dysfunctions, as well as non-traditional disorders including traumatic brain injury (TBI). Its lead candidate NeuroSTAT is currently in Phase II clinical development and consists of a formulation of the natural immunosuppressant ciclosporin. The compound is able to stabilize mitochondria through the inhibition of the mitochondrial protein cyclophilin D, thereby protecting from neuronal cell death and limiting the spread of brain injury. Neurovive has been able to snatch orphan drug designation for the compound both in the EU and the US.

Comment: The company’s stock fiercely dropped last year in October, after its ciclosporin-formulation CicloMulsion flopped in clinical trials for the treatment of patients with myocardial infarction. Now the company seems to be getting back on its feet to position its non-immunosuppressive cyclophilin D inhibitor as a first-in-class treatment for NASH. Additionally, the company is expanding into the field of hepatocellular carcinoma, adding the liver diseases to the company’s repertoire of non-traditional mitochondrial diseases.

NeuroVive_Mitochondria

Mitochondria, the powerhouses of our cells.

Images via shutterstock.com / NoPainNoGain / Stig Alenas

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.